



# Prescription Drug Affordability Board Meeting

January 9, 2026

# January 9 Meeting Agenda

**Call to Order, Roll Call, Minutes Approval**

**10:00 - 10:05 am**

**Board Member & Director Updates**

- *Updates to Board Membership*
- *Remarks from Dr. Gail Mizner*

**10:05 - 10:15 am**

**Board Business**

- *PDAAC Chair Report Out*
- *Stakeholder Workgroup Update and Discussion on Draft Report*

**10:15 - 11:10 am**

**Public Comment**

**11:10 - 11:30 am**

*Comments will be limited to 2 minutes per person or organization.*

**Executive Session**

**11:30 am - 12:00 pm**

*The Board may meet in Executive Session to receive legal advice regarding the appeal of Amgen v. Mizner, Case No. 25-1641, currently pending in the Federal Circuit Court of Appeals pursuant to section 24-6-402(3)(a)(II), C.R.S.*

**Adjournment**

**12:00 pm**

*The Board may meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.*

*If you need an accommodation to access PDAB meetings or materials, please notify staff at [dora\\_ins\\_pdab@state.co.us](mailto:dora_ins_pdab@state.co.us).*

*Prescription Drug Affordability Advisory Council members may attend the January 9, 2026, PDAB meeting and may provide public comment.*



# Call to Order Roll Call Minutes Approval

*October 3, 2025, Meeting Minutes*



# Board Member & Director Updates

*Updates to Board Membership*

*Remarks from Dr. Gail Mizner*



# Board Member & Director Updates

*Updates to Board Membership  
Remarks from Dr. Gail Mizner*

# Board Business

*PDAAC Chair Report Out  
Stakeholder Workgroup Update and Discussion on Draft Report*

# Board Business

*PDAAC Chair Report Out  
Stakeholder Workgroup Update and Discussion on Draft  
Report*

# Stakeholder Workgroup

## *Background, Purpose, and Goals*



In 2025, the Board updated PDAB Policy No. 4 to establish a staff-facilitated stakeholder workgroup that includes:

- PDAAC members
- RDAC members
- Members of organizations representing patients affected by a condition or disease treated by a prescription drug under the Board's review
- Other stakeholders

Ahead of the second round of affordability reviews, the Board asked staff to convene the workgroup to provide input on developing a framework for capturing patient experience information in a holistic and consistent manner.

The workgroup aims to address challenges identified during the first round of affordability reviews, particularly related to building trust, establishing clarity in patient engagement and communication, collecting conflicts of interest disclosures, and ensuring a stronger analysis and use of patient input.

# Stakeholder Workgroup

## *Workgroup Details and Meeting Goals*



### Workgroup Sessions

- The workgroup met over two meetings this fall, leveraging PDAACs forum and creating space for open public comment during the workgroup session.
- Sessions were led by the PDAAC chair, Dr. Kimberley Jackson, and Dr. Amy Gutierrez.
- Attendees included: PDAAC members, providers, advocacy organizations, and members of the public.

### Session Goals

- Session 1: Develop initial recommendations for actionable, feasible, and transparent practices.
- Session 2: Review the draft report, identify if all objectives are met, and help formulate recommendations on how to include voices that are not captured in the Board's current work.

### Work Product

- **Draft PDAAC Recommendation Report:** Outlines recommendations for best practices and process improvements for collecting patient experience information during the Board's prescription drug affordability review process.

# Stakeholder Workgroup

## Session 1 Overview



### Workgroup Objectives:

- Tools for collecting patient experience information (e.g., surveys, meetings, etc.)
- Timeline for collecting patient information
- Outreach and communication for establishing clear communication channels with collaborators
- Assessing information received from stakeholders
- Conflicts of interest disclosure from stakeholders

### The following information were included with each objective:

- **Round 1 Affordability Review Outcomes:** An overview of what the Board did during the first round of affordability reviews.
- **Stakeholder Suggestions:** Improvements suggested by stakeholders.
- **Research:** An overview of initial research about each objective, including methods used by other organizations, such as: CMS, HCPF, CDPHE, PhRMA, NASHP, other state PDABs, etc.
- **Recommendations for Round 2:** Guiding discussion topics for the workgroup.

# Stakeholder Workgroup

## Session 1: Stakeholder Discussion Summary

### 1. Tools for collecting patient experience information

- Survey improvement via clearer, open-ended questions
- Inform patients of how the Board will use their response; Privacy considerations; Multilingual surveys & accessibility.

### 2. Timeline for collecting patient experience information

- Clear, structured survey timeline that is open for 4-6 weeks.

### 3. Outreach and Communications

- Education toolkit
- Outreach through social media and webinars
- Engage patient organizations, pharmacists, providers, medical societies using flyers/QR codes

### 4. Assessing Information

- Avoid rigid definitions to preserve the diversity of patient experiences.
- More clarity on national v. CO residents

### 5. Conflicts of Interest Disclosure

- COIs should not prevent the Board from considering a stakeholder's comment
- Verbiage change: "Duality of interest"

# Stakeholder Workgroup

## Session 2 Overview

Staff identified 5 distinct categories of recommendations from workgroup session 1:

1. Utilize PDAAC to Collect Patient Input for Drug Selection
2. Establish a PDAB Patient Engagement Toolkit
3. Create a Communication Network
4. Provide Additional Assessment of Information
5. Promote a Process for Voluntary Disclosure of Conflicts of Interest

# Stakeholder Workgroup

## Session 2: Stakeholder Discussion Summary

### 1. Utilize PDAAC to Collect Patient Input for Drug Selection

- Allow PDAAC to gather patient input on drug eligible list for selection.
- Allow sufficient time for PDAAC to collect qualitative input to meaningfully inform their recommendations to the Board.

### 2. Establish a PDAB Patient Engagement Toolkit

- Clearly explain PDAB's authority and limits.
- Co-develop surveys and engagement tools with Patient Research Partners (PRPs) and avoid engagement timing barriers.

### 3. Create a Communication Network

- Use a broad, transparent process to select outreach partners, including patient advocacy organizations.
- Improve communication platforms with a centralized, accessible, navigable website.

### 4. Provide Additional Assessment of Information

- Continue separating Medicare data from affordability analyses and apply similar safeguards to claims data to prevent skewed analysis and findings.

### 5. Promote a Process for Voluntary Disclosure of Conflicts of Interest (COI)

- Implement a balanced COI/DOI framework that reduces stigma and provides context on funding sources.
- Apply disclosure requirements equally to all stakeholders, including PDAB/PDAAC members, with a public repository.

# Stakeholder Workgroup

## *Recommendation Report*

### Utilize PDAAC to Collect Patient Input for Drug Selection

#### Issue

Under current statute and rule, patient input is not among the metrics the Board may consider when selecting drugs for affordability review. As a result, opportunities for patients to contribute during the drug identification and selection phases are limited.

#### Recommendation & Proposed Approach

##### **Utilize PDAAC to collect patient input during the selection phase.**

- After the publication of the eligible drug list, the PDAAC could solicit feedback from patients on which drugs pose affordability issues and should be considered by the Board for review.
- The PDAAC would then incorporate these insights into its recommendations to the Board during the selection phase.

# Stakeholder Workgroup

## *Recommendation Report*

### Establish a PDAB Patient Engagement Toolkit

#### Issue

Patients need a clearer understanding of the Board's work and guidance on how and when to engage during each phase of affordability review.

#### Recommendation & Proposed Approach

Develop a **PDAB Patient Engagement Toolkit** that provides educational resources and opportunities for patient participation.

The toolkit will include materials developed in partnership with patient research partners and patient organizations and will clearly explain the PDAB's scope of work and authority.

- **PDAB 101:** Available in different formats (written, slides, webinar) that explains the work of the PDAB.
- **Health Insurance 101:** Information to help patients understand insurance design and consumer protections
- **Surveys and Engagement Tools:** Staff will continue to collaborate with patient research partners to update surveys and allow time for public feedback on survey design and timelines.
- **Outreach and Promotion:** Consistent outreach materials and toolkits for partners, supported by dedicated staff resources to aimed at ensuring broad and effective dissemination.
- **Focus Groups:** PDAB will continue to host focus groups for discussion related to drug selections.



# Stakeholder Workgroup

## *Recommendation Report*



### Create a Communication Network

#### Issue

PDAB and staff need to ensure they are engaging with the correct community partners at the right time, allowing enough time to educate and recruit stakeholders.

#### Recommendations & Proposed Approach

Establish a **Community Partner Network** (e.g., pharmacists, providers, consumer organizations) to support outreach and education to impacted patients, caregivers, providers, and advocacy organizations.

PDAB and PDAAC will develop a transparent process for identifying and engaging community partners, including (but not limited to) patient advocacy organizations, consumer groups, providers, pharmacists, wholesalers and other pharmaceutical supply chain entities.

To support accessibility and transparency, staff will evaluate improvements to communication infrastructure, including transitioning from ad hoc document-sharing systems to a centralized, navigable public-facing website that houses educational materials, engagement opportunities, and partner resources.

# Stakeholder Workgroup

## *Recommendation Report*



### Provide Additional Assessment of Information

#### Issue

Survey data used during affordability reviews included populations and plan types for which a UPL may not apply, and summary-level reporting may be confusing/unclear within the affordability review process.

#### Recommendation & Proposed Approach

**Continue collecting broad patient input while clearly segmenting and contextualizing data in affordability review reports.**

Affordability review reports will include both aggregated summaries of all responses and a clearly labeled subsets to identify out-of-state respondents and Medicare beneficiaries. Retracted patient narratives will continue to be published as part of the affordability reports, with appropriate privacy protections, to preserve context that may be lost in summary statistics.

# Stakeholder Workgroup

## *Recommendation Report*



### Voluntary Disclosure of Conflicts of Interest (COI)

#### Issue

The Board seeks a consistent, fair, and transparent approach to disclosures of COI from all participants in PDAB and PDAAC processes.

#### Recommendation & Proposed Approach

Encourage voluntary disclosure through a **standardized “Conflict/Duality of Interest” framework** that emphasizes transparency rather than exclusion.

PDAB will consistently request disclosures from all participants while reframing the process to reduce stigma and provide context regarding how funding supports programs and services. Disclosure standards will be applied consistently across all stakeholders, including patient organizations, and entities funded by foundations with cost-containment missions.

# Public Comment

*Please sign up via the link in the chat. Comments will be limited to two minutes.*



# The Prescription Drug Affordability Board is in Executive Session

*The Board may meet in Executive Session to receive legal advice regarding the appeal of Amgen v. Mizner, Case No. 25-1641, currently pending in the Federal Circuit Court of Appeals pursuant to section 24-6-402(3)(a)(II), C.R.S.*

# Board Business

## *Board Deliberation & Vote - Dismissal of Appeal*



Board  
Action Item

Board deliberates

Board may vote to:

- Approve of dismissing the appeal pending before the Federal Circuit Court of Appeals in Amgen v. Mizner, Case No. 25-1641.

# Upcoming Meetings

**PDAB Meeting:** February 20 at 10 am MT

**PDAAC Meeting:** March 5 at 9 am MT

*For meeting minutes, agendas, and general information about PDAB, visit*

*<https://doi.colorado.gov/insurance-products/health-insurance/prescription-drug-affordability-review-board>*

*Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to [dora\\_ins\\_pdab@state.co.us](mailto:dora_ins_pdab@state.co.us).*

*If you are in need of an accommodation to access PDAB meetings or materials, please notify staff at [dora\\_ins\\_pdab@state.co.us](mailto:dora_ins_pdab@state.co.us).*

# Break

*The meeting will resume after a 10-minute break.*



# The Prescription Drug Affordability Board is in Executive Session

*The Board may meet in Executive Session to receive legal advice pursuant to section 24-6-402(3)(a)(II), C.R.S.*



# The Prescription Drug Affordability Board is in Executive Session

*The Board may also meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3),C.R.S.*